AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27806364 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol
Number of subjects: 485
Study 27806364 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (Control)
Number of subjects: 485
Study 24162380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Simvastatin (GS)
Number of subjects: 114
Study 24162380 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus Placebo (GP)
Number of subjects: 114
Study 22628588 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-diameter metal-on-metal total hip replacement (MoM THR)
Number of subjects: 119
Study 20007794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen 500 mg and ibuprofen 150 mg per tablet (Maxigesic)
Number of subjects: 0
Study 20007794 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 500 mg per tablet alone
Number of subjects: 0
Study 20007794 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 150 mg per tablet alone
Number of subjects: 0
Study 18560649 — intervention group
Group type: EXPERIMENTAL
Intervention: Gysi prosthesis (simplified procedure with anatomic teeth)
Number of subjects: 20
Study 18560649 — intervention group
Group type: COMPARATOR
Intervention: Gerber prosthesis (comprehensive method with lingualized teeth)
Number of subjects: 20
Study 16292136 — intervention group
Group type: EXPERIMENTAL
Intervention: HbF-mode analyses
Number of subjects: 20
Study 16292136 — intervention group
Group type: COMPARATOR
Intervention: HbA-mode analyses (control)
Number of subjects: 20
Study 16292136 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults (control)
Number of subjects: 20
Study 12182272 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg fluoxetine per day
Number of subjects: 989
Study 12182272 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine per day
Number of subjects: 989
Study 12182272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study 10190822 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate, 20 mg/d
Number of subjects: 248
Study 10190822 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 248
Study 8846544 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha monoclonal antibodies (mabs)
Number of subjects: 0
Study 8846544 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 blockade with IL-1 ra and soluble IL-1 R
Number of subjects: 0
Study 8846544 — intervention group
Group type: COMPARATOR
Intervention: Anti-T cell therapies
Number of subjects: 0
Study 2178965 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (individually titrated dose)
Number of subjects: 26
Study 2178965 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline intake at 10 p.m.
Number of subjects: 26
Study 2178965 — intervention group
Group type: COMPARATOR
Intervention: Theophylline intake at 6 p.m. and 8 p.m.
Number of subjects: 26
Study 7188910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroderm
Number of subjects: 0
Study 7188910 — intervention group
Group type: COMPARATOR
Intervention: Hydrokortison DAK
Number of subjects: 0
Study 31810940 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56
Study 31810940 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BPI severity score
Number of subjects: 56
Study 31810940 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative BPI severity score
Number of subjects: 56
Study 31810940 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative BPI interference score
Number of subjects: 56
Study 31810940 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative BPI interference score
Number of subjects: 56
Study 28402454 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 160-80-40 mg subcutaneously
Number of subjects: 91
Study 28402454 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2.5 mg/kg/day
Number of subjects: 91
Study 28402454 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 91
Study 28402454 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 91
Study 26506378 — intervention group
Group type: EXPERIMENTAL
Intervention: Bev-3.0 (96 kcal whey protein beverage with pH 3.0)
Number of subjects: 12
Study 26506378 — intervention group
Group type: EXPERIMENTAL
Intervention: Bev-7.0 (96 kcal whey protein beverage with pH 7.0)
Number of subjects: 12
Study 26506378 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-Acid (96 kcal whey protein gel)
Number of subjects: 12
Study 26506378 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-Heated (96 kcal whey protein gel)
Number of subjects: 12
Study 26506378 — intervention group
Group type: COMPARATOR
Intervention: CON (0 kcal water)
Number of subjects: 12
Study 23936977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular depot medroxyprogesterone acetate (DMPA) therapy
Number of subjects: 61
Study 23936977 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >30 years
Number of subjects: 61
Study 23936977 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe stages of endometriosis
Number of subjects: 61
Study 23936977 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain prior to treatment
Number of subjects: 61
Study 21299465 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60‐90 mg once a month for 1 year)
Number of subjects: 177
Study 21299465 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 177
Study 20439555 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified pandesal (hydrogen-reduced iron at 80 mg/kg, electrolytic iron at 80 mg/kg, or ferrous fumarate at 40 mg/kg)
Number of subjects: 250
Study 20439555 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and VA-fortified pandesal
Number of subjects: 250
Study 20439555 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-fortified pandesal (at 490 RE/100 g)
Number of subjects: 250
Study 20439555 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified flour (control group)
Number of subjects: 250
Study 17194963 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (ET) for 8 weeks
Number of subjects: 37
Study 17194963 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 37
Study 15124072 — intervention group
Group type: EXPERIMENTAL
Intervention: brimonidine 0.2%
Number of subjects: 92
Study 15124072 — intervention group
Group type: EXPERIMENTAL
Intervention: dorzolamide 2%
Number of subjects: 92
Study 11808064 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem mouthwash (with or without alcohol)
Number of subjects: 0
Study 11808064 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study 11808064 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem mouthwash
Number of subjects: 0
Study 9740926 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine 12 mg
Number of subjects: 370
Study 9740926 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine 8 mg
Number of subjects: 370
Study 9740926 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 370
Study 9740926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 8056702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 235
Study 8056702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 235
Study 8056702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 235
Study 3395665 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral dose of terodiline (Mictrol)
Number of subjects: 8
Study 3395665 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterated drug as a covariate
Number of subjects: 8
Study 31237713 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin therapy
Number of subjects: 2933
Study 31237713 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2933
Study 27641967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50-100mg daily)
Number of subjects: 41
Study 27641967 — intervention group
Group type: COMPARATOR
Intervention: Control (diet and exercise)
Number of subjects: 41
Study 25305273 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols intake (average 296 mg/d)
Number of subjects: 35597
Study 22511572 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon plus bare-metal stenting (BMS)
Number of subjects: 48
Study 22511572 — intervention group
Group type: COMPARATOR
Intervention: Taxus stent implantation
Number of subjects: 48
Study 21896019 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory tool for discussing dogs' quality-of-life
Number of subjects: 170
Study 21896019 — intervention group
Group type: COMPARATOR
Intervention: Normal consultations (control group)
Number of subjects: 170
Study 19455117 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD) plus standard medical therapy
Number of subjects: 597
Study 19455117 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy only
Number of subjects: 597
Study 16932229 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus NMBAs (n = 18)
Number of subjects: 36
Study 16932229 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy plus placebo (n = 18)
Number of subjects: 36
Study 15384020 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA, 2.5 mg/kg/d for 8 weeks
Number of subjects: 44
Study 15384020 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 44
Study 11566047 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg GHRH administered as a single intravenous bolus
Number of subjects: 0
Study 11566047 — intervention group
Group type: COMPARATOR
Intervention: 10 microg GHRH administered as five repetitive boluses within 1 h
Number of subjects: 0
Study 9740479 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (transdermal patch)
Number of subjects: 35
Study 9740479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8092427 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (AX)
Number of subjects: 177
Study 8092427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 8092427 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G (PG)
Number of subjects: 177
Study 3345614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium indomethacin (pH 8.2, 12%)
Number of subjects: 0
Study 3345614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium naproxen (pH 9.6, 40%)
Number of subjects: 0
Study 3345614 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (pH 4.8, 8%)
Number of subjects: 0
Study 3345614 — intervention group
Group type: COMPARATOR
Intervention: Placebo gels (various pH levels)
Number of subjects: 0
Study 3345614 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 0
Study 3345614 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0
Study 3345614 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 0
Study 3345614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid forms of naproxen and indomethacin
Number of subjects: 0
Study 31673835 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics-based model
Number of subjects: 113
Study 31673835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomic-clinical model
Number of subjects: 113
Study 31673835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 113
Study 30177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal ropivacaine (7-15 mg) in Group S (BMI <25)
Number of subjects: 405
Study 30177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal ropivacaine (7-15 mg) in Group M (25 ≤ BMI <30)
Number of subjects: 405
Study 30177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal ropivacaine (7-15 mg) in Group L (BMI ≥30)
Number of subjects: 405
Study 30177674 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of hypotension
Number of subjects: 405
Study 27102553 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO + TXA (10,000 IU EPO daily subcutaneous injections on preoperative days 1-4 and postoperative days 1-3; 15 mg/kg TXA 10 min prior to incision)
Number of subjects: 62
Study 27102553 — intervention group
Group type: COMPARATOR
Intervention: TXA (15 mg/kg TXA 10 min prior to incision)
Number of subjects: 62
Study 26423182 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (target dose 10 mg [maximum 15 mg] daily) for 12 weeks
Number of subjects: 181
Study 26423182 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 181
Study 26423182 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 181
Study 26423182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 24220412 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved decompressive craniectomy
Number of subjects: 131
Study 24220412 — intervention group
Group type: COMPARATOR
Intervention: Routine decompressive craniectomy (Control)
Number of subjects: 131
Study 21039405 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (BOT)
Number of subjects: 18
Study 21039405 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobloc/Myobloc (NBC)
Number of subjects: 18
Study 21039405 — intervention group
Group type: COMPARATOR
Intervention: Pure saline (Control)
Number of subjects: 18
Study 18511702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5343
Study 18511702 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 5343
Study 18511702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg
Number of subjects: 5343
Study 18511702 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus fluticasone propionate
Number of subjects: 5343
Study 18511702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol
Number of subjects: 5343
Study 12521408 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered Natural American Spirit
Number of subjects: 10
Study 12521408 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered Irie bidi
Number of subjects: 10
Study 12521408 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered Sher bidi
Number of subjects: 10
Study 12521408 — intervention group
Group type: COMPARATOR
Intervention: Participant's own brand
Number of subjects: 10
Study 9884248 — intervention group
Group type: COMPARATOR
Intervention: Neoral (N)
Number of subjects: 97
Study 9884248 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (FK)
Number of subjects: 97
Study 7640502 — intervention group
Group type: EXPERIMENTAL
Intervention: Poria‐Polyporus Anti‐diarrhea Mixture (PPAM)
Number of subjects: 60
Study 7640502 — intervention group
Group type: COMPARATOR
Intervention: Smicta
Number of subjects: 60
Study 2744633 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 500 mg
Number of subjects: 10
Study 2744633 — intervention group
Group type: COMPARATOR
Intervention: Choline magnesium trisalicylate (CMT) 500 mg
Number of subjects: 10
Study 736748 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted cancer chemotherapy
Number of subjects: 135
Study 736748 — intervention group
Group type: COMPARATOR
Intervention: Non-predicted or no surgical adjuvant chemotherapy
Number of subjects: 135
Study 29189311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg
Number of subjects: 120
Study 29189311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg
Number of subjects: 120
Study 29189311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 120
Study 29189311 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg, 800 mg, 1200 mg
Number of subjects: 120
Study 29189311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29772131 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture (GAA) - 6 sessions every 15 days, using anti-aggression and stomach points.
Number of subjects: 50
Study 29772131 — intervention group
Group type: COMPARATOR
Intervention: Body Acupuncture (GBA) - 24 sessions total, using bilateral L14, LIll, ST25, ST36, SP6, SP9, CV12, and CV6 points, two times a week.
Number of subjects: 50
Study 25958769 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus brief self-hypnosis training (two × 90-minute groups at around 32 and 35 weeks' gestation; daily audio self-hypnosis CD)
Number of subjects: 680
Study 25958769 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 680
Study 25958769 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus brief self-hypnosis training
Number of subjects: 680
Study 23376050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body stabilization
Number of subjects: 14
Study 23376050 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial pencil
Number of subjects: 14
Study 23376050 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned grip height pencil
Number of subjects: 14
Study 23376050 — intervention group
Group type: COMPARATOR
Intervention: Regular pencil
Number of subjects: 14
Study 20652703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanespimycin suspension for injection
Number of subjects: 17
Study 20652703 — intervention group
Group type: COMPARATOR
Intervention: Tanespimycin injection (Cremophor-based formulation)
Number of subjects: 17
Study 20652703 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with tanespimycin (both formulations)
Number of subjects: 17
Study 18942713 — intervention group
Group type: EXPERIMENTAL
Intervention: Early maturing girls
Number of subjects: 283
Study 18942713 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Tanner stage
Number of subjects: 283
Study 18942713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual maturation stages in boys
Number of subjects: 283
Study 17076973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 200 mg three times for 1 day
Number of subjects: 122
Study 17076973 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole 50 mg/kg in a single dose
Number of subjects: 122
Study 17076973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 122
Study 17076973 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole
Number of subjects: 122
Study 14657227 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI followed by FOLFOX6 (arm A)
Number of subjects: 220
Study 14657227 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX6 followed by FOLFIRI (arm B)
Number of subjects: 220
Study 14657227 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 220
Study 14657227 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX6
Number of subjects: 220
Study 11718213 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF for 3 days, five days prior to chemotherapy
Number of subjects: 60
Study 11718213 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 60
Study 9109740 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (30 mg transdermal patch, releasing about 6 mg over 24 hours)
Number of subjects: 19
Study 9109740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (transdermal patch)
Number of subjects: 19
Study 7959241 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shockwave lithotripsy (ESWL) alone
Number of subjects: 50
Study 7959241 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL with adjuvant bile acid treatment
Number of subjects: 50
Study 7959241 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ESWL alone and ESWL with bile acids)
Number of subjects: 50
Study 7959241 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile salt treatment
Number of subjects: 50
Study 26595213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 25°C
Number of subjects: 0
Study 26595213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature at 15, 20, and 25°C
Number of subjects: 0
Study 26595213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient temperature decrease from 25 to 5°C
Number of subjects: 0
Study 24850228 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI) 45-405 mg every 2-4 weeks
Number of subjects: 931
Study 24850228 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 931
Study 22408034 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily for 3 months)
Number of subjects: 909
Study 22408034 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 909
Study 20580206 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 111
Study 20580206 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 111
Study 20580206 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 111
Study 19687351 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 153
Study 19687351 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP3179
Number of subjects: 153
Study 16509835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg each morning)
Number of subjects: 62
Study 16509835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16509835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62
Study 16509835 — intervention group
Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 62
Study 12623986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy
Number of subjects: 57
Study 12623986 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor-free regimen
Number of subjects: 57
Study 11799734 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine + epinephrine 1:200,000
Number of subjects: 45
Study 11799734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine without vasoconstrictor
Number of subjects: 45
Study 11799734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine + felypressin 1:1,850,000
Number of subjects: 45